Recently, the Trump administration initiated a federal medical cannabis reclassificationThe move recognizes medical cannabis products that are authorized by state authorities and licensed providers. This is a major shift in the federal drug policies, as cannabis has been deemed unfit for medical purposes by the government over five decades.
Histoically, the federal agency classified cannabis with other substances, such as heroin. This classification was challenged more and more by new scientific findings and public opinions. Reclassification is a reflection of a growing consensus between medical professionals and public about the possible applications for cannabis.
The Historical Context of Consensus
Since decades, the federal position on cannabis is in stark contrast to state-level development. In the United States, since 1996 when California implemented a law allowing access to medical cannabis by physicians, 40 states now have similar laws. Since 1996, 40 U.S. states have implemented laws allowing physician-authorized access to medicinal cannabis products.
The professional opinion of cannabis has also changed. 69% of doctors and nurses in family practice, as well as other professionals, now admit that marijuana has medical applications. More than a quarter (25%) of physicians have said they discuss cannabis with their patients.
Review of Department of Health and Human Services
The Department of Health and Human Services published a 250-page comprehensive review in 2023 that provided important data to support the medical use of cannabis. In the report, it was revealed that over 6 million people use medical marijuana under doctor supervision. The agency for public health concluded that there were no safety issues that could suggest that medical cannabis use poses unacceptable safety risks in cases where scientific evidence is available to support its use.
Cannabis can be used to manage chronic pain. The National Academy of Sciences researchers determined almost a decade back that there was “conclusive” evidence that cannabis could help in the management of chronic pain. Now, the federal government has officially recognized this reality through the medical cannabis reclassification.
Medical Cannabis Reclassification Limitations
The administration’s order to reclassify medical cannabis is a positive step, but it doesn’t fully resolve the complex issues surrounding cannabis policies in the United States. There are still significant gaps, especially for those patients who live in states with no regulated medical marijuana programs. Also for consumers and businesses in the states where adult use cannabis is legal.
- States Unaffected Reclassification is not a relief to patients in Idaho or the other 10 states that do not currently regulate medical cannabis. The legal risk for these individuals to access cannabis remains.
- Adult-Use Markets: There are no remedies available to the millions of customers or thousands of businesses in the 24 states which have legalised cannabis for adult use. The federal laws still prohibit the consumption or sale of cannabis within these 24 states.
Path Forward: Full Descheduling Proposal
To solve the conflict between the federal and state government and grant the state governments authority to create their own cannabis regulation policies similar to those of alcohol, advocates claim that cannabis should be removed entirely from the Controlled Substances Act. It would also align with federalist principles and correct the current inconsistencies of drug policy.
Disclaimer: The information contained in this article does not constitute medical advice. Hemp Gazette is not a medical provider and does not offer diagnoses or treatment plans. Before making decisions about your health, or regarding any medical conditions, always consult with a qualified healthcare provider. Therapeutic Goods Administration of Australia has not evaluated statements about the therapeutic benefits of cannabinoid products, hemp or cannabis. TGA regulates the access to medical cannabis in Australia.